Triage is the process by which clinicians decide which patients should be prioritized for admission into the hospital or discharge, based on how urgently they need attention and the severity of their symptoms or disease.

Our study is funded by the European & Developing Countries Clinical Trials Partnership (EDCTP), a public-public partnership between countries in Europe and sub-Saharan Africa, supported by the European Union. We also have additional funding from the United Kingdom Department for International Trade .

To use our test, clinicians will only have to collect 2 drops of blood obtained via a prick to the patient’s finger. This will be enough for the test to detect the biomarker levels in less than 20 min and display the results as an intuitive color-coded risk category: red for those at high risk, yellow for those at moderate risk, green for those at low risk. Based on these categories, clinicians can then decide whether to admit the patient to the hospital for treatment, keep them for observation, or discharge them. For the final version of our test, we plan to incorporate the results of our test into a mobile application that will display the results along with important information about the newborn, such as weight, age, vital signs, that will help the clinician make the best decision.

A biomarker is a molecule that is found in blood, organs, or tissues and involved in normal biological processes. When we have a disease or condition, the levels of these molecules can increase or decrease, indicating a change in the biological processes. In our case, the biomarker on which our test is based, is present in the blood and is released from the inner layer of blood vessels in higher quantities when an individual is sick.

FAQs Archive - ACROBAT-newborns

Why are we focusing on countries from Sub-Saharan Africa?

The majority of newborn deaths occur in Sub-Saharan Africa due [...]

By adttsacro|2025-04-22T13:06:51+01:0021/03/2025|Comments Off

What is triage?

Triage is the process by which clinicians decide which patients [...]

By adttsacro|2025-03-21T11:16:03+00:0021/03/2025|Comments Off

What is risk-stratification?

Risk-stratification is the process by which clinicians decide which patients [...]

By adttsacro|2025-03-21T11:15:47+00:0021/03/2025|Comments Off

Who funds the study?

Our study is funded by the European & Developing Countries [...]

By adttsacro|2025-03-21T11:15:30+00:0021/03/2025|Comments Off

How does it work?

To use our test, clinicians will only have to collect [...]

By adttsacro|2025-03-21T11:14:45+00:0021/03/2025|Comments Off

What is a prognostic test?

A prognostic test can determine whether an individual will acquire [...]

By adttsacro|2025-03-21T11:14:25+00:0021/03/2025|Comments Off

What is a biomarker?

A biomarker is a molecule that is found in blood, [...]

By adttsacro|2025-03-21T11:14:09+00:0021/03/2025|Comments Off

Why a biomarker test?

Current risk stratification strategies are insufficient to appropriately identify which [...]

By adttsacro|2025-03-21T11:13:49+00:0021/03/2025|Comments Off

This project has received funding from the European Union’s Global Health EDCTP3 under grant agreement No 101158797.

Disclaimer: Funded by the European Union. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.

CONNECT WITH US

LOCATION

Barcelona Institute of Global Health (ISGlobal)
C/ Rosselló 132, 5º 2º
08036 Barcelona, Catalunya, Spain

INFORMATION

CONNECT WITH US

LOCATION